Sulfated fibroin, a novel sulfated peptide derived from silk, inhibits human immunodeficiency virus replication in vitro

Bioscience, Biotechnology and Biochemistry

Volumn 64, Issue 8, 2000, Pages 1664-1670

  Gotoh, Kazuyo ^a   Izumi, Hiroyuki ^a,b   Kanamoto, Taisei ^a   Tamada, Yasushi ^c   Nakashima, Hideki ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

^c NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES   (Japan)

Author keywords

AIDS; Anti HIV formulation; Binding inhibitor; Silk fibroin; Sulfated peptides

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTICOAGULANT AGENT; FIBROIN; INSECT PROTEIN; SULFATE;

ANIMAL; ARTICLE; CELL COMMUNICATION; CELL LINE; CHEMISTRY; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; METABOLISM; PATHOGENICITY; PHYSIOLOGY; SILK; SILKWORM; SUTURE; VAGINA; VIRION; VIROLOGY; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; ANTICOAGULANTS; BOMBYX; CELL COMMUNICATION; CELL LINE; FEMALE; FIBROINS; HIV-1; HUMANS; INSECT PROTEINS; SILK; SULFATES; SUTURES; VAGINA; VIRION; VIRUS REPLICATION;

EID: 0034251781     PISSN: 09168451     EISSN: 13476947     Source Type: Journal    
DOI: 10.1271/bbb.64.1664     Document Type: Article

References (37)

1. Condra, J. H., Schleif, W. A., Blahy, O. M., Gabryelski, L. J., Graham, D. J., Quintero, J. C., Rhodes, A., Robbins, H. L., Roth, E., Shivaprakash, M., Titus, D., Yang, T., Teppler, H., Squires, K. E., Deutsch, P. J., and Emini, E. A., In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature, 374, 569-571 (1995).
2. in the treatment of patients with AIDS and AIDS-related complex, a double blind, placebo controlled trial. N. Engl. J. Med., 317, 192-197 (1987).
3. Lang, W., Osmond, D., Page-Bodkin, K., Moss, A., and Winkelstein, W. Jr., Population-based estimates of antiretroviral therapy and anti-pneumocystis prophylaxis in San Francisco: 1991. J. Acquir. Im-mime Defic. Syndr., 6, 191-195 (1993).
4. Yoshida, O., Nakashima, H., Yoshida, T., Kaneko, Y., Yamamoto, I., Matsuzaki, K., Uryu, T., and Yamamoto, N., Sulfation of the immunomodulating polysaccharide lentinan: A novel strategy for an-tivirals to human immunodeficiency virus (HIV). Biochem. Pharm., 37, 2887-2891 (1988).
5. Jagodzinski, P. P., Wiaderkiewicz, R., Kurzawski, G., Kloczrwiak, M., Nakashima, H., Hyjek, E., Yamamoto, N., Uryu, T., Kaneko, Y., and Posner, M. R., Mechanism of the inhibitory effect of curdlan sulfate on HIV-1 infection in vitro. Virology, 202, 735-745 (1994).
6. Nakashima, H., Inazawa, K., Ichiyama, K., Ito, M., Ikushima, N., Shoji, T., Katsuraya, K., Uryu, T., Yamamoto, N., Juodawlkis, A. S., and Schinazi, R. F., Sulfated alkyl oligosaccharides inhibit human immunodeficiency virus in vitro and provide sustained drug levels in mammals. Antiviral Chem. Chemother., 6, 271-280 (1995).
7. Uryu, T., Katsuraya, K., and Nakashima, H., Synthesis of sulfated alkyl oligosaccharides with potent anti-HIV activity. Macromol. Symp., 120, 147-158 (1997).
8. Nakashima, H., Matsui, T., Yoshida, O., Isowa, Y., Kido, Y., Motoki, Y., Ito, M., Shigeta, S., Mori, T., and Yamamoto, N., A new anti-human immunodeficiency virus substance, glycyrrhizin surfate; endowment of glycyrrhzin with reverse transcriptase-inhibitory activity by chemical modification. Jpn. J. Cancer. Res., 78, 767-771 (1987).
9. Nakashima, H., Yoshida, O., Tochikura, T. S., Yoshida, T., Mimura, T., Kido, Y., Motoki, Y., Kaneko, Y., Uryu, T., and Yamamoto, N., Sulfation of polysaccharides generates potent and selective inhibitors of human immunodeficiency virus infection and replication in vitro. Jpn. J. Cancer. Res., 78, 1164-1168 (1987).
10. and AIDS-related complex. Ann. Intern. Med., 110, 183-188 (1989).
11. Lorentsen, K. J., Hendrix, C. W., Collins, J. M., Kornhauser, D. M., Petty, B. G., Klecker, R. W., Flexner, C., Eckel, R. H., and Leitman, P. S., Dextran sulfate is poorly absorbed after oral administration. Ann. Int. Med., Ill, 561-566 (1989).
12. Flexner, C., Barditch, C. P. A., Kornhauser, D. M., Farzadegan, H., Nerhood, L. J., Chaisson, R. E., Bell, K. M., Lorentsen, K. J., Hendrix, C. W., Petty, B. G., and Leitman, P. S., Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob. Agents Chemother., 35, 2544-2550 (1991).
13. Mita, K., Ichimura, S., and Tharappel, C. J., Highly repetitive sutructure and its organization of the silk fibroin gene. J. Molecular. Evolution, 38, 583-592 (1994).
14. Chackerian, B., Long, E. M., Luciw, P. A., and Overbaugh, J., HIV-1 co-receptors participates in postentry stages of the virus replication cycle and function in SIV infection. J. Virol., 71, 3932-3939 (1997).
15. Nakashima, H., Masuda, M., Murakami, T., Koyanagi, Y., Matsumoto, A., Fujii, N., and Yamamoto, N., Anti-human immunodeficiency virus of a novel synthetic peptide, T22 ([Tyr-5, 12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob. Agents. Chemother., 36, 1249-1255 (1992).
16. Kimpton, J. and Emerman, M., Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated /Lgalactosidase gene. J. Virol., 166, 2232-2239 (1992).
17. Arakaki, R., Tamamura, H., Premanathan, M., Kanbara, K., Ramanan, S., Mochizuki, K., Baba, M., Fujii, N., and Nakashima, H., T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J. Virol., 73, 1719-1723 (1999).
18. Tochikura, T. S., Nakashima, H., Tanabe, A., and Yamamoto, N., Human immunodeficiency virus (HlV)-induced cell fusion: quantification and its application for the simple and rapid screening of anti-HIV substances in vitro. Virology, 164, 542-546 (1988).
19. Schols, D., Baba, M., Pauwels, R., and De Clercq, E., Flow cytometric method to demonstrate whether anti-HIV-1 agents inhibit virion binding to T4+ cells. J. Acquire. Immune. Defic. Syndr., 2, 10-15 (1989).
20. inhibits HIV replication and cytopathic effects in vitro, and reduces HIV infection in hu-PBL-SCID mice. Antiviral. Res., 30, 95-108 (1996).
21. antigen is an essential component of the receptor for the AIDS retrovirus. Nature, 312, 763-767 (1984).
22. Klatzmann, D., Champagne, E., Chamaret, S., Gruest, J., Guetard, D., Hercend, T., Gluckman, J. C., and Montagnier, L., T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature, 312, 767-768 (1984).
23. Pearce, P. R. and Phillips, D. M., Studies of adhesion of lymphocytic cells: implications for sexual transmission of human immunodeficiency virus. Biol. Reprod., 48, 431-445 (1993).
24. Stafford, M. K., Cain, D., Rosenstein, I., Fontaine, E. A., McClure, M., Flanagan, A. M., Smith, J. R., Taylor, R. D., Weber, J., and Kitchen, V. S., A placebo-controlled, double-blind prospective study in healthy female volunteers of dextrin sulphate gel: a novel potential intravaginal virucide. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol., 14, 213-218 (1997).
25. Berger, E. A., HIV entry and tropism: the chemokine receptor connection. AIDS., 11, S3-16 (1997).
26. Cairns, J. S. and D’Souza, M. P., Chemokines and HIV-1 second receptors: the therapeutic connection. Nat. Med., 4, 563-568 (1998).
27. Berger, E. A., Doms, R. W., Fenyo, E. M., Korber, B. T., Littman, D. R., Moore, J. P., Sattentau, Q. J., Schuitemaker, H., Sodroski, J., and Weiss, R. A., A new classification for HIV-1. Nature, 15, 391, 240 (1998).
28. Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Di Marzio, P., Marmon, S., Sutton, R. E., Hill, C. M., Davis, C. B., Schall, T. J., Littman, D. R., and Landau, N. R., Identification of a major co-receptor for primary isolates of HIV-1. Nature, 381, 661-666 (1996).
29. Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima, K. A., Cayanan, C., Maddon, P. J., Koup, R. A., Moore, J. P., and Paxton, W. A., HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature, 381, 667-673 (1996).
30. Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M., and Berger, E. A., CC CKR5: a RANTES, MIP-la, MIP-lyg receptor as a fusion cofactor for macrophage-tropic HIV-1. Science, 111, 1955-1958 (1996).
31. Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P. D., Wu, L., Mackay, C. R., LaRosa, G., Newman, W., Gerard, N., Gerard, C., and Sodrroski, J., The /Lchemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell, 85, 1135-1148 (1996).
32. Doranz, B. J., Rucker, J., Yi, Y., Smyth, R. J., Samson, M., Peiper, S. C., Parmentier, M., Collman, R. G., and Doms, R. W., A dual-tropic primary HIV-1 isolate that uses fusin and the fi-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell, 85, 1149-1158 (1996).
33. Oberlin, E., Amara, A., Bachelerie, F., Bessia, C., and Virelizier, J. L., The CXC chemokine SDF-1 is the ligand for LESTR/fusion and prevents infection by T-cell-line-adapted HIV-1. Nature, 382, 833-835 (1996).
34. Connor, R. I., Increased viral burden and cytopathic-ity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J. Virol., 67, 1772-1777 (1993).
35. Schuitemaker, H., Koot, M., Kootstra, N. A., Dercksen, M. W., de Goede, R. E., van Steenwijk, R. P., Lange, J. M., Schattenkerk, J. K., Miedema, F., and Tersmette, M., Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol., 66, 1354-1360 (1992).
36. Richman, D. D. and Bozzette S. A., The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J. Infect. Dis., 169, 968-74 (1994).
37. Connor, R. I., Sheridan, K. E., Ceradini, D., Choe, S., and Landau, N. R., Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med., 185, 621-628 (1997).